# Case Report: diffuse entire gastrointestinal tract involvement of ALK-positive anaplastic large cell lymphoma harboring JAK-STAT pathway mutations in an adolescent with leukemoid reaction

**Authors:** Sizhe Yang, Yang Dai, Qiyuan Li, Sha Zhao, Xueqin Deng, Feifan Chen, Yaping Zhang, Yufang Wang, Wenyan Zhang

PMC · DOI: 10.3389/fonc.2025.1709110 · 2026-01-09

## TL;DR

A 14-year-old girl with a rare form of T-cell lymphoma showed full gastrointestinal tract involvement and responded well to chemotherapy.

## Contribution

This case report highlights JAK-STAT pathway mutations in an ALK+ ALCL patient, a genetic profile more typical of ALK-negative cases.

## Key findings

- The patient had diffuse gastrointestinal tract involvement and leukemoid reaction.
- RNA sequencing confirmed NPM1::ALK gene fusion and WES identified JAK-STAT pathway mutations.
- The patient showed significant remission after four chemotherapy sessions.

## Abstract

Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma (ALK+ ALCL) is an aggressive mature T-cell non-Hodgkin lymphoma. Its typical characteristics include positive CD30 and ALK expression detected by immunohistochemistry, and it is often accompanied by ALK gene translocation, among which the chromosomal translocation t (2;5) is the most common. This disease predominantly affects young individuals, with extranodal involvement being relatively common. However, cases involving the digestive tract are relatively rare. We report a rare case of a 14-year-old female with ALK+ALCL presenting with fever and peripheral blood leukocytosis as initial manifestations and complicated by diffuse involvement of the entire gastrointestinal tract. The patient showed significant remission having completed 4 chemotherapy sessions. In further studies, RNA sequencing confirmed the presence of NPM1::ALK gene fusion in this case; whole-exome sequencing (WES) detected somatic mutations in multiple genes of the JAK-STAT pathway (including JAK1, PTPN6, MTOR, and TYK2). It is noteworthy that such genetic alterations are more commonly observed in ALK-negative anaplastic large cell lymphoma (ALK-ALCL) but are less commonly reported in ALK+ALCL.

## Linked entities

- **Genes:** ALK (ALK receptor tyrosine kinase) [NCBI Gene 238], NPM1 (nucleophosmin 1) [NCBI Gene 4869], JAK1 (Janus kinase 1) [NCBI Gene 3716], PTPN6 (protein tyrosine phosphatase non-receptor type 6) [NCBI Gene 5777], MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475], TYK2 (tyrosine kinase 2) [NCBI Gene 7297]
- **Proteins:** TNFRSF8 (TNF receptor superfamily member 8), ALK (ALK receptor tyrosine kinase)
- **Diseases:** anaplastic large cell lymphoma (MONDO:0020325), leukemoid reaction (MONDO:0006829)

## Full-text entities

- **Genes:** ALK (ALK receptor tyrosine kinase) [NCBI Gene 238] {aka ALK1, CD246, NBLST3}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, TNFRSF8 (TNF receptor superfamily member 8) [NCBI Gene 943] {aka CD30, D1S166E, Ki-1}, JAK1 (Janus kinase 1) [NCBI Gene 3716] {aka AIIDE, JAK1A, JAK1B, JTK3}, PTPN6 (protein tyrosine phosphatase non-receptor type 6) [NCBI Gene 5777] {aka HCP, HCPH, HPTP1C, PTP-1C, SH-PTP1, SHP-1}, TYK2 (tyrosine kinase 2) [NCBI Gene 7297] {aka IMD35, JTK1}
- **Diseases:** fever (MESH:D005334), mature T-cell non-Hodgkin lymphoma (MESH:D008228), leukemoid reaction (MESH:D007955), leukocytosis (MESH:D007964), anaplastic large cell lymphoma (MESH:D017728)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12827520/full.md

---
Source: https://tomesphere.com/paper/PMC12827520